Stifel raises STAAR Surgical stock price target on China demand
Stifel raised its price target on STAAR Surgical (STAA) to $34 from $31, citing strong China demand and revenue growth. The company beat Q3 2026 expectations with $83.4M revenue and $0.28 EPS. Revenue surged 51.3% over 12 months, though gross margins narrowed to 70.9%. STAA is addressing supply-demand gaps and exploring new lens trials.
How this was made
The 30-second read
Why it matters
The upgrade and earnings beat suggest a near‑term rally, but supply‑chain issues in China could temper longer‑term gains.
Market read
The news provides fresh, material information for traders of STAA and related ophthalmic device stocks.
What to watch
Potential tariff and manufacturing cost pressures could erode margins despite revenue growth.
Background
Stifel's upgrade follows STAAR Surgical's Q3 2026 earnings release, which showed revenue of $83.4 million and adjusted EPS of $0.28, beating expectations.
Ticker impact
Stifel raised its price target on STAAR Surgical to $34 after the company posted Q3 2026 earnings that beat revenue expectations.
upward pressure as investors price in the higher target and earnings beat
The price‑target increase and earnings beat are fresh, material news for a mid‑cap medical device stock.
Market effects
Positive for the ophthalmic devices sector as strong China demand signals broader market tailwinds.
Boosts sentiment for US‑listed medical‑device stocks, especially those with exposure to China.
Highlights continued demand for vision‑correction lenses globally, modestly supporting health‑tech themes.
Counterpoint
If supply constraints in China persist, earnings may be less sustainable, limiting upside.
Key entities
- AnalystStifel
Equity research firm that raised the price target.
- CompanySTAAR Surgical
Medical device maker specializing in intraocular lenses.
